Search

Boston Scientific Corp.

Uždarymo kaina

SektoriusSveikatos priežiūra

51.81 0.12

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

51.68

Max

52.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-437M

904M

Pardavimai

239M

5.4B

P/E

Sektoriaus vid.

19.945

57.002

Pelnas, tenkantis vienai akcijai

0.86

Pelno marža

16.612

Darbuotojai

59,000

EBITDA

-214M

1.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+20.41% upside

Dividendai

By Acuity

Kitas uždarbis

2026-10-28

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.5B

73B

Ankstesnė atidarymo kaina

51.69

Ankstesnė uždarymo kaina

51.81

Naujienos nuotaikos

By Acuity

41%

59%

144 / 340 reitingas Healthcare

Boston Scientific Corp. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-14 23:01; UTC

Boston Scientific Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions finishing higher. No specific news was identified.

2026-08-13 23:01; UTC

Social Media

Boston Scientific shares are higher in after-market trading, buoyed by social media discussions of the CEO's $9 million stock purchase amid a significant year-to-date decline.

2026-08-12 23:06; UTC

Boston Scientific Corp shares are modestly higher in after-market trading. The stock remains significantly above its 20-day moving average.

2026-08-11 23:41; UTC

Boston Scientific Corp shares are lower in after-market trading, showing unusual volatility and reflecting a broader trend of weakness since Tuesday's close.

2026-08-10 23:06; UTC

Boston Scientific shares are trading higher in after-market hours, amid mixed market sentiment influenced by geopolitical tensions, particularly concerning the Strait of Hormuz.

2026-08-08 00:01; UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting gains since Friday's close and remaining above their 20-day moving average.

2026-08-07 23:21; UTC

Boston Scientific shares are higher in after-market hours following a Labor Department report showing a decline in non-farm payroll employment, reducing interest rate hike expectations.

2026-08-06 23:01; UTC

Boston Scientific Corp shares are higher during after-market hours, reflecting a generally strong performance backdrop amid resilient labor market data.

2026-08-05 23:02; UTC

Social Media
News

Boston Scientific Corp shares rose in after-market trading following CEO Mahoney's purchase of 186,240 shares at an average price of $48.33.

2026-08-04 19:36; UTC

News

Boston Scientific shares are higher, supported by strong organic revenue growth and rising free cash flow margin, despite recent economic data pressures.

2026-08-03 23:01; UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting positive momentum. Broader economic news shows increased growth in the manufacturing sector.

2026-07-31 22:52; UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting positive market sentiment from strong earnings by major tech companies.

2026-07-30 23:51; UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

2026-07-29 23:51; UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting broader market gains. No specific news has been identified to explain the movement.

2026-07-28 23:52; UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting a steady increase since Tuesday's close despite broader market concerns, particularly in Asia.

2026-07-27 23:02; UTC

News
Social Media

Boston Scientific plans a restructuring with pre-tax charges of $700 million to $800 million, leading shares lower in after-market hours.

2026-07-25 00:01; UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

2026-07-24 23:01; UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

2026-07-22 20:06; UTC

Correlated Moves

Boston Scientific reported first-quarter adjusted EPS of $0.43, missing estimates. Shares are trading lower amid cautious market sentiment and Stryker's decline.

2026-07-21 23:06; UTC

Boston Scientific Corp shares are higher in after-hours trading, reflecting a modest uptick following Tuesday's close. The stock remains below its 20-day moving average.

2026-07-20 23:01; UTC

Boston Scientific shares are higher in after-market trading, reflecting notable strength since Monday's close, despite no specific news driving the movement.

Akcijų palyginimas

Kainos pokytis

Boston Scientific Corp. Prognozė

Kainos tikslas

By TipRanks

20.41% į viršų

12 mėnesių prognozė

Vidutinis 62.41 USD  20.41%

Aukščiausias 89 USD

Žemiausias 50 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Boston Scientific Corp. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

24 ratings

21

Pirkti

3

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

144 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
help-icon Live chat